IDH2 and acute myeloid leukemia: Nowadays, both AG-120 and AG-221 are being investigated in newly diagnosed AML patients with IDH mutations, in combination with induction and consolidation chemotherapy (NCT02632708) and azacitidine (NCT02677922).